Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome Journal Article


Authors: Nichols, K. E.; Harkin, D. P.; Levitz, S.; Krainer, M.; Kolquist, K. A.; Genovese, C.; Bernard, A.; Ferguson, M.; Zuo, L.; Snyder, E.; Buckler, A. J.; Wise, C.; Ashley, J.; Lovett, M.; Valentine, M. B.; Look, A. T.; Gerald, W.; Housman, D. E.; Haber, D. A.
Article Title: Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome
Abstract: X-linked lymphoproliferative syndrome (XLP) is an inherited immunodeficiency characterized by increased susceptibility to Epstein-Barr virus (EBV). In affected males, primary EBV infection leads to the uncontrolled proliferation of virus-containing B cells and reactive cytotoxic T cells, often culminating in the development of high-grade lymphoma. The XLP gene has been mapped to chromosome band Xq25 through linkage analysis and the discovery of patients harboring large constitutional genomic deletions. We describe here the presence of small deletions and intragenic mutations that specifically disrupt a gene named DSHP in 6 of 10 unrelated patients with XLP. This gene encodes a predicted protein of 128 amino acids composing a single SH2 domain with extensive homology to the SH2 domain of SHIP, an inositol polyphosphate 5-phosphatase that functions as a negative regulator of lymphocyte activation. DSHP is expressed in transformed T cell lines and is induced following in vitro activation of peripheral blood T lymphocytes. Expression of DSHP is restricted in vivo to lymphoid tissues, and RNA in situ hybridization demonstrates DSHP expression in activated T and B cell regions of reactive lymph nodes and in both T and B cell neoplasms. These observations confirm the identity of DSHP as the gene responsible for XLP, and suggest a role in the regulation of lymphocyte activation and proliferation. Induction of DSHP may sustain the immune response by interfering with SHIP-mediated inhibition of lymphocyte activation, while its inactivation in XLP patients results in a selective immunodeficiency to EBV.
Keywords: gene deletion; mutation; lymphocyte proliferation; lymphocyte activation; amino acid sequence; molecular sequence data; nucleotide sequence; gene repression; lymphoma; x chromosome; gene control; lymphoproliferative disease; sequence homology; epstein barr virus; linkage (genetics); genetic markers; chromosome map; chromosome mapping; lymphoproliferative disorders; immunodeficiency; x chromosome linkage; epstein-barr virus; humans; priority journal; article; src homology domains
Journal Title: Proceedings of the National Academy of Sciences of the United States of America
Volume: 95
Issue: 23
ISSN: 0027-8424
Publisher: National Academy of Sciences  
Date Published: 1998-11-10
Start Page: 13765
End Page: 13770
Language: English
DOI: 10.1073/pnas.95.23.13765
PUBMED: 9811875
PROVIDER: scopus
PMCID: PMC24894
DOI/URL:
Notes: Article -- Export Date: 12 December 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. William L Gerald
    375 Gerald